IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

**OXFORD** et al

Sir:

Serial No. 10/766,030

Filed: January 29, 2004

For: EP4 RECEPTOR ANTAGONISTS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 1700

Atty. Ref.: 620-288

Group: 1625

Examiner: DENTZ, Bernard I.

September 21, 2006

# INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)** [within 3 months of filing or prior to 1st Office Action on the merits] N/C 2.(a) Statement Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] N/C  $\boxtimes$ 2 .(b) Fee Payment Pursuant to 37 CFR 1.97(c) [before Final Office Action or Allowance (requires Rule 97(e) Statement or Rule 17(p) fee)] \$180.00 3. Pursuant to 37 CFR 1.97(d) [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]

\$180.00



The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

$\boxtimes$	4.	A list of documents on Form PTO-1449 together with copies of each dentified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.				
This	oaper	submitted in accordance with:				
	5.	37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]				
$\boxtimes$	6.	37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier and				
		) The required Statement made in item 8 below; or				
	$\boxtimes$	The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.				
	7.	37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement <u>and</u> Rule 17(p) fee), but before final fee payment]; and				
		The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and				
		The required Statement is stated in item 8 below.				
	8.	Statement under 37 CFR 1.97(e)				
		The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or				
		No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				



9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted, NIXON & VANDERHYE P.C.

Ву:	/B. J. Sadoff/				
	B. J. Sadoff				
	Reg. No. 36,663				

901 North Glebe Road, 11th Floor Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100



	·		· <u>-</u>	ATTY. DOCKET NO	).	SERIA	L NO.
				620-888		10/766,	030
INFORMA'	TION	DISCLOSURE STATE	MENT	APPLICANT			
		61	PE	Oxford et al			
(Use several	sheets	if necessary)	4	FILING DATE		GROU	P
		( SEP	2 2 2006	01/09/2004		1625	
		Topy a	THE VI	S. PATENT DOCUMENTS			
*Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropria
	1	5,834,468	11/1998	Breault et al			
	2	6,184,245	02/2001	Yugi Sugawara et al			
	4	2003/158240	08/2003	Gordon Baxter et al			
	5	6,610,719	08/2003	Vishwas Paralkar et al			
	6	6,380,218	04/2002	Anthony Moarfat et al			
	7	2005/043386	02/2005	Takahide Nishi et al			

	8	5,602,136	02/1997	Gerd Ruhter et al	
	9	5,686,445	11/1997	Jay Albright et al	
	12	2003/100583	05/2003	Jean-Michel Bernardon	
	13	2003/119817	06/2003	Anita Mehta et al	
	14	2004/0147559	07/2004	Arthur Taveras et al	
	15	2004/0152734	08/2004	Corrina Sundermann et al	
	16	2004/0235888	11/2004	Teruo Yamamori et al	
	17	2005/176987	08/2004	Lukas Goossen et al	
	18	2002/0115671	08/2002	R Goehring et al	
	19	5,607,951	03/1997	John Macor et al	
	20	5,679,692	10/1997	Richard Friary et al	
	21	5,883,106	03/1999	Rodney W Stevens et al	
	22	5,977,170	11/1999	Thomas Commons et al	
	23	6,008,362	12/1999	Thomas Commons et al	
	24	6,121,671	08/2000	Kei-Yu Ko et al	
	25	6,162,819	12/2000	Ursula Schindler et al	
	26	6,291,677	09/2001	Jayasree Vasudevan et al	
	27	6,849,641	02/2005	Peng Cho Tang et al	

Examiner	Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



#### **U.S. PATENT DOCUMENTS**

28	6,956,057	10/2005	David F Woodward et al		
31	6,211,197	04/2001	Michel Belley		
 35	6,861.441	03/2005	Nicholas M.Clayton et al		
36	2002/137736	09/2002	Kenneth Mattes et al		
 39	2004/048889	03/2004	Dan Peters et al		
 46	6,878,740	04/2005	Corrina Sundermann et al		
47	2002/040024	04/2002	Richard Apodaca et al		
49	6,716,864	04/2004	Robert M Burk et al		
52	6,797,712	09/2004	Corinna Maul et al		
53	6,835,212	12/2004	Rozzell et al		
60	2003/0195190	10/2003	Bernd Peschke et al		
69	2004/192758	09/2004	Johann Leban et al		
75	2005004133	01/2005	Lews R Makings et al		
 88	5,939,436	08/1999	William Robert Carling et al		
89	5,645,566	07/1997	Rodney Brenneman et al		
90	5,663,357	09/1997	Ming Teng et al		
102	2004/259880	12/2003	David J Lockhart et al		
			<u> </u>	<del></del>	

# **FOREIGN PATENT DOCUMENTS**

							Transl	ation
		Document Number	Date	Country	Class	Subclass	Yes	No
	3	EP1108426	06/2001	European				
	10	EP661260	07/1995	European				✓
	11	EP776885	06/1997	European				<b>✓</b>
<del>- ".</del> '	29	WO/00/06529	02/2000	PCT				
	30	WO/00/18405	04/2004	PCT				
	32	WO/00/24738	05/2000	PCT				
	33	WO/0040561	07/2000	PCT				
	34	WO/0069987	11/2000	PCT	V			<b>V</b>
	37	WO/0157006	08/2001	PCT				
	38	WO/0164676	09/2001	PCT				
	40	WO/02058698	08/2002	PCT				

Examiner	Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## **FOREIGN PATENT DOCUMENTS**

	1	<u> </u>		I	<del>- 1</del>	<del></del>
	41	WO/02060898	08/2002	PCT		
	42	WO/0206278	01/2002	PCT		
	43	WO/02067930	09/2003	PCT		
	44	WO/02067937	09/2002	PCT		
	45	WO02/083624	10/2002	PCT		
	48	WO02/18361	03/2002	PCT		
	50	WO02/26727	04/2002	PCT		
	51	WO02/40473	04/2002	PCT		
	54	WO03/018585	03/2003	PCT		
	55	WO0/3033503	04/2003	PCT		<b>/</b>
	56	WO0/3044015	05/2003	PCT		
	57	WO03/053352	07/2003	PCT		
	58	WO03/055479	07/2003	PCT		
	59	WO03/059871	07/2003	PCT – English translation of claims only	<b>✓</b>	
	61	WO03/097621	11/2003	PCT		
	62	WO03/097644	11/2003	PCT		
	63	WO04/002948	01/2004	PCT		<b>✓</b>
	64	WO04/011418	02/2004	PCT		
	65	WO04/019932	03/2004	PCT		
	66	WO04/024663	03/2004	PCT		<b>√</b>
	67	WO04024738	03/2004	PCT		<b>✓</b>
	68	WO04048349	06/2004	PCT		
	70	WO04069816	08/2004	PCT		
	71	WO04078169	09/2004	PCT		
	72	WO04089944	10/2004	PCT		
	73	WO04094362	11/2004	PCT		✓
1	74	WO04099199	11/2004	PCT		
,	76	WO05079793	09/2005	PCT		
	77	WO02068412	09/2002	PCT		
	78	WO9601827	01/1996	PCT		
	79	WO9521171	08/1995	PCT		

Examiner	Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## **FOREIGN PATENT DOCUMENTS**

	80	WO9117163	11/1991	PCT		
	81	WO9118897	12/1991	PCT		
	82	WO9221644	12/1992	PCT		
	83	WO9306118	04/1993	PCT		
	84	WO9402460	02/1994	PCT		
	85	WO9402483	02/1994	PCT		
	86	WO9406796	03/1994	PCT		✓
	87	WO9611911	04/1996	PCT		
	91	WO9807835	02/1998	PCT		
	92	WO9834909	08/1998	PCT		<b>/</b>
	93	WO9847894	10/1998	PCT		
	94	WO9851662	11/1998	PCT		
	95	WO9856783	12/1998	PCT		1
	96	WO9857925	12/1998	PCT		
	97	WO9857927	12/1998	PCT		
	98	WO9857928	12/1998	PCT		
	99	WO9910322	03/1999	PCT		1
	100	WO9919300	04/1999	PCT		
	101	WO04063194	07/2004	PCT		
	103	WO9303012	02/1993	PCT		
	104	WO03090869	11/2003	PCT		
	105	JP10-287654	1998	Japan – English abstract only	<b>/</b>	
	106	ЈР09-311401	1997	Japan – English abstract only	1	
	107	JP11-209366	1999	Japan - English abstract only	1	
	108	JP2004-051628	2004	Japan – English abstract only	<b>/</b>	
	109	JP2001-139550	2001	Japan – English abstract only	1	
	110	JP07-281440	1995	Japan - English abstract only	1	
- 11 11	111	JP04-253974	1992	Japan – English abstract only	✓	
	112	JP03-240066	1991	Japan – English abstract only	<b>✓</b>	
	113	JP2005-046141	2005	Japan- English abstract only	<b>✓</b>	
	114	JP2005-41867	2005	Japan - English abstract only	1	

Examiner	Date Considered
, "W'.	

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Richard J Davis et al. EP <sub>4</sub> prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br. J. Pharmacol. (2004) 141, 580-585

Examiner	Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.